Alliances
Researchers with Pfizer and IBM developed an artificial intelligence (AI) model that they claim can predict eventual onset of Alzheimer’s disease with 71% accuracy based on a language sample. They published the research today in The Lancet eClinicalMedicine.
Roche and Atea Pharmaceuticals are partnering to develop, manufacture and distribute AT-527, Atea’s experimental antiviral drug against COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
Under terms of the Korsuva deal, Connecticut-based Cara Therapeutics will receive $100 million in an upfront payment, as well as an equity investment of $50 million. Additional milestone payments could bring the total of the deal to about $290 million.
In this multi-target partnership, Genentech will leverage Genesis’ Dynamic PotentialNet AI platform and other novel neural network algorithms.
Relief Therapeutics and NeuroRx released results on Tuesday from their open-label prospective study looking into RLF-100 (aviptadil) as a potential treatment for COVID-19 and respiratory failure.
Dyno will be responsible for the design of the novel AAV capsids that are expected to have improved functional properties for gene therapy. Roche and its subsidiary Spark Therapeutics will take the capsids and conduct preclinical studies with hopes of taking them into the clinic, and eventually to commercialization.
Takeda has entered into a five-year agreement with Accenture and Amazon Web Services (AWS) to support the Tokyo-based pharmaceutical company in moving 80% of its applications to the “cloud” and modernizing the company’s research tools.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
Results from multiple Phase III trials show consistent improvements in pain relief and physical function.
PRESS RELEASES